Entero Healthcare Solutions Ltd
Incorporated in 2018, Entero Healthcare
Solutions Ltd is in the business of distribution
and marketing of pharmaceutical and surgical products and allied services[1]
- Market Cap ₹ 4,973 Cr.
- Current Price ₹ 1,143
- High / Low ₹ 1,565 / 1,038
- Stock P/E 95.0
- Book Value ₹ 379
- Dividend Yield 0.00 %
- ROCE 4.54 %
- ROE 3.22 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company is almost debt free.
- Company has delivered good profit growth of 103% CAGR over last 5 years
- Debtor days have improved from 124 to 89.2 days.
Cons
- Stock is trading at 3.01 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
- Earnings include an other income of Rs.61.4 Cr.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|
| 56 | 105 | 137 | 178 | 318 | 409 | 366 | |
| 73 | 137 | 191 | 222 | 353 | 439 | 408 | |
| Operating Profit | -17 | -32 | -54 | -44 | -34 | -30 | -42 |
| OPM % | -30% | -30% | -39% | -25% | -11% | -7% | -12% |
| 21 | 23 | 27 | 53 | 90 | 67 | 61 | |
| Interest | 1 | 2 | 5 | 11 | 22 | 2 | 2 |
| Depreciation | 4 | 7 | 9 | 10 | 9 | 9 | 9 |
| Profit before tax | -2 | -18 | -41 | -12 | 24 | 27 | 8 |
| Tax % | 0% | 0% | 0% | 0% | -58% | 28% | |
| -2 | -18 | -41 | -12 | 38 | 19 | 5 | |
| EPS in Rs | -162.67 | -1,811.38 | -106.10 | -30.31 | 8.84 | 4.41 | 1.21 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 49% |
| 3 Years: | 44% |
| TTM: | -4% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 103% |
| 3 Years: | 49% |
| TTM: | -8% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | -23% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | 3% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|
| Equity Capital | 0.10 | 0.10 | 4 | 4 | 43 | 44 |
| Reserves | -13 | -31 | -72 | -84 | 1,583 | 1,607 |
| 457 | 540 | 674 | 775 | 18 | 14 | |
| 21 | 23 | 47 | 68 | 125 | 139 | |
| Total Liabilities | 466 | 533 | 654 | 764 | 1,769 | 1,804 |
| 46 | 50 | 51 | 41 | 34 | 28 | |
| CWIP | 2 | 2 | 0 | 0 | 0 | 0 |
| Investments | 38 | 39 | 39 | 41 | 41 | 277 |
| 380 | 442 | 563 | 682 | 1,694 | 1,498 | |
| Total Assets | 466 | 533 | 654 | 764 | 1,769 | 1,804 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|
| -52 | -68 | -45 | -57 | -76 | -109 | |
| -167 | -7 | -69 | -58 | -763 | 208 | |
| 178 | 76 | 127 | 91 | 926 | -41 | |
| Net Cash Flow | -41 | 0 | 14 | -24 | 87 | 58 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|
| Debtor Days | 114 | 107 | 139 | 153 | 130 | 89 |
| Inventory Days | 206 | 177 | 103 | 68 | 65 | 110 |
| Days Payable | 101 | 48 | 99 | 132 | 88 | 87 |
| Cash Conversion Cycle | 219 | 236 | 143 | 89 | 107 | 112 |
| Working Capital Days | 2,013 | 1,201 | 1,034 | 947 | 850 | 432 |
| ROCE % | -3% | -6% | -0% | 4% | 5% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
7 Nov - Earnings call on unaudited Q2 and H1 FY26 results (ended Sep 30, 2025) on 13 Nov 2025, 15:00 IST.
-
Board Meeting Intimation for Approval Of The Financial Results For The Quarter Ended September 30, 2025
29 Oct - Board meeting on Nov 12, 2025 to approve Q2/H1 FY2025-26 unaudited results; trading window closure noted.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
8 Oct - Of Schedule of Analyst / Institutional Investor meeting to be held on October 14, 2025 at 04:30 PM (IST)
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
8 Oct - RTA certificate under Reg 74(5) confirming dematerialisation actions for quarter ended September 30, 2025.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
3 Oct - Group analyst/investor meeting Oct 9, 2025 11:00am onwards in Mumbai (warehouse); only public information discussed.
Concalls
-
Aug 2025Transcript PPT
-
Jun 2025Transcript PPT
-
Feb 2025TranscriptPPT
-
Feb 2025Transcript PPT
-
Nov 2024Transcript PPT
-
Aug 2024Transcript PPT
-
Jun 2024Transcript PPT REC
-
May 2024TranscriptNotesPPT
-
Mar 2024Transcript PPT
Business Overview:[1]
EHSL, a leading Healthcare Supply Chain Solutions Specialist, ranks among India’s top three healthcare product distributors by revenue, offering demand fulfillment and generation solutions to manufacturers.